Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20435633 | 0.91 | LMNA (0.80) | PKMLMNACA12CA1CA2 | |
| SCHEMBL830027 | 0.88 | CA12 (0.77) | PKMLMNACA12CA1CA2 | |
| SCHEMBL20435645 | 0.86 | LMNA (0.68) | PKMLMNACA12CA1CA2 | |
| SCHEMBL21033644 | 0.86 | LMNA (0.85) | PKMLMNACA12CA1CA2 | |
| SCHEMBL21033390 | 0.84 | LMNA (0.65) | PKMLMNACA12CA1CA2 | |
| SCHEMBL21033637 | 0.83 | CA12 (0.62) | PKMLMNACA12CA1CA2 | |
| SCHEMBL20435590 | 0.83 | KDM4E (0.78) | PKMLMNACA12CA1CA2 | |
| SCHEMBL20435593 | 0.83 | NPSR1 (0.72) | PKMLMNACA12CA1CA2 | |
| SCHEMBL21033640 | 0.83 | CA12 (0.65) | PKMLMNACA12CA1CA2 | |
| SCHEMBL20440774 | 0.83 | ATM (0.80) | PKMLMNACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | Zander Biologics, Inc (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | Zander Therapeutics, Inc. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | Zander Therapeutics, Inc. (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2019104201-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN NON-HUMANS | Zander Therapeutics, Inc. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019104199-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY | REGEN BIOPHARMA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | NR4A2, NR2C2, NR0B2 | PKM 4721/4885LMNA 4829/4885CA12 4297/4885 |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | NR4A2, NR2C2, NR2F2 | PKM 4778/4885LMNA 4840/4885CA12 4080/4885 |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | NR4A2, NR2C2, NR0B2 | PKM 4721/4885LMNA 4829/4885CA12 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.